Obesity Market Set for Explosive 27% CAGR Growth by 2036, Fueled by 7 Promising Emerging Therapies | DelveInsight
Why now
Thesis: Obesity market CAGR supports GLP-1 revenue expectations.
Catalyst to watch: Emerging therapy data and approvals.
Main risk: Competition and trial setbacks.
Why it matters
A large projected obesity-market CAGR supports long-term revenue expectations for incumbent and emerging GLP-1 players.
Details
The obesity treatment pipeline is rapidly evolving, with promising candidates such as RGT-075 (Regor Therapeutics), MET-002o (D&D Pharmatech/Pfizer), enicepatide (CT-388; Roche/Carmot Therapeutics), elecoglipron (AstraZeneca), and several other emerging therapies advancing next-generation...
Related assets & topics
AstraZeneca · AZNSources
- prnewswire · 2026-09-10 14:31 UTC